Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib in Advanced Cancer With BRCA/BRCA-Pathway Alterations
NCT02286687Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2014
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talazoparib in cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Clinical benefit by Response Evaluation Criteria in Solid Tumors 1.1 at 1 year. Started Dec 2014; status: active, not recruiting.
02
Drugs
talazoparib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02286687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02286687.